FTC Amicus Brief Urges Appeals Court to Correct Legal Errors in District Court’s Antitrust Analysis of Reverse-Payment Agreement

FTC, here.

Competition Bureau sets out preliminary views on patent agreement settlement enforcement

Thecompetitor.ca, here.

Antitrust Analysis of Reverse Payment Settlements After Actavis: Three Questions and Proposed Answers

J. Wright, here. 

Unjustified Delays in Generic Drug Competition

S. Hemphill, here. 

The Implications of the Imperfect European Patent Enforcement System on the Assessment of Reverse Payment Settlements

R. Subiotto, here.

The Future of Reverse Payments in the Wake of FTC v. Actavis, Inc.

Symposium Papers, here. 

Drug Makers and Antitrust: Is Cash All That Matters?

Blogs.wsj.com, here.

A Response to Chief Justice Roberts: Why Antitrust Must Play a Role in the Analysis of Drug Patent Settlements

M. Carrier, here. 

Five Arguments Laid to Rest after Actavis

M. Carrier, here. 

The FTC's Role in Shaping Antitrust Doctrine: Recent Successes and Future Targets

J. Wright, here.

The Future of Reverse Payment Settlements in the wake of FTC v. Actavis

Symposium, Preprints here (antitrustprof_blog)

“Reverse Payment” Settlements Subject to Greater Antitrust Scrutiny: Implications of Supreme Court FTC v. Actavis Ruling

McDermott, Will & Emery, here. 

Pay-to-Delay Settlements: The Circuit-Splitting Headache Plaguing Big Pharma

S. Han, here. 

Legal Assessment of Patent Settlement Agreements Containing “Reverse” Payments

R. Subiotto, Presentation here. 

Amici Curiae Professors and AAI on reverse-payment settlements

Here. 

11th Circuit on reverse payment settlements

FEDERAL TRADE COMMISSION v WATSON PHARMACEUTICALS, INC., SOLVAY PHARMACEUTICALS, INC., PAR PHARMACEUTICAL COMPANIES, INC., PADDOCK LABORATORIES, INC., here.

FTC's Amicus Brief on reverse-payment settlements

In Re K-Dur Antitrust Litigation, here.